Skip to main content
SpringerLink
Log in

Methodological approach of clinical trials for renal transplantation

  • Chapter
Immunosuppression under Trial

Part of the book series: Transplantation and Clinical Immunology ((TRAC,volume 31))

  • 53 Accesses

Abstract

The search for more effective and less toxic immunosuppressive agents to control transplant rejection is a challenge. Clinical trials provide a framework to take on this challenge. As stated by Senn, there are five main purposes to a clinical trial summarized by a mnemonic using the five vowels: anticipation, ethics, inference, organization and utmost good faith [l]. Methodological issues in renal transplantation will be illustrated by recent publications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Senn S. The work of the pharmaceutical statistician. In: Statistical Issues in Drug Development. Chichester: John Wiley & Sons; 1997: 55–65.

    Google Scholar 

  2. Freeman PR. The role of P-values in analysing trial results. Stat. Med. 1993; 12: 1443–1452.

    CAS  Google Scholar 

  3. Senn S. The measurement of treatment effects. In: Statistical issues in drug development. Chichester: John Wiley & Sons; 1997: 111–125.

    Google Scholar 

  4. Hunsicker LG. Design of trials of method to reduce late renal allograft loss: the price of success. Kidney Int. 1995; 48: S120–S123.

    Google Scholar 

  5. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997; 15: 39–47.

    Article  Google Scholar 

  6. Guttmann RD, Soulillou JP. Definitions of acute rejection and controlled clinical trials in the medical literature. Am. J. Kidney Dis. 1998; 31: S3–S6.

    Article  PubMed  CAS  Google Scholar 

  7. Guttmann RD. Acute kidney rejection: is there a consensus? Adv. Nephrol. Necker Hosp. 1997; 26: 165–170.

    CAS  Google Scholar 

  8. Gaber LW. Role of renal allograft biopsy in multicenter clinical trials in transplantation. Am. J. Kidney Dis. 1998; 31: S19–S25.

    Article  PubMed  CAS  Google Scholar 

  9. Cantarovich D, Soulillou JP. Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation: review of the conference questionnaire. Am. J. Kidney Dis. 1998; 31: S26–S30.

    Article  PubMed  CAS  Google Scholar 

  10. Guttmann RD, Soulillou JP, Moore LW First MR, Gaber AO, Pouletty P, Schroeder TJ. Proposed consensus for definitions and endpoints for clinical trials of acute kidney transplant rejection. Am. J. Kidney Dis. 1998; 31: S40–S46.

    Article  PubMed  CAS  Google Scholar 

  11. Gaber LW, Moore LW, Gaber AO et al. Utility of standardized histological classification in the management of acute rejection. 1995 Efficacy Endpoints Conference. Transplantation. 1998; 65: 376–380 (erratum appears in Transplantation. 1998; 66: 1121).

    Google Scholar 

  12. Colvin RB, Cohen AH, Saiontz C et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J. Am. Soc. Nephrol. 1997; 8: 1930–1941.

    PubMed  CAS  Google Scholar 

  13. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993; 44: 411–422.

    Article  PubMed  CAS  Google Scholar 

  14. Schroeder TJ, Moore LW Efficacy endpoints conference on acute rejection in kidney transplantation: summary report of the data base. Am. J. Kidney Dis. 1998; 31: S31–S39.

    Article  PubMed  CAS  Google Scholar 

  15. Kasiske BL. Clinical correlates to chronic renal allograft rejection. Kidney Int. Suppl. 1997; 63: S71–S74.

    CAS  Google Scholar 

  16. Chertow GM, Brenner BM, Mackenzie HS, Milford EL. Non-immunologic predictors of chronic renal allograft failure: data from the United Network of Organ Sharing. Kidney Int. Suppl. 1995; 52: S48–S51.

    CAS  Google Scholar 

  17. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 1996; 125: 605–613.

    PubMed  CAS  Google Scholar 

  18. Albert JM, Ioannidis JPA, Reichelderfer P et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. Stat. Med. 1998; 17: 2435–2462.

    CAS  Google Scholar 

  19. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 1989; 8: 431–440.

    CAS  Google Scholar 

  20. Lin DY, Fleming TR, DeGruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat. Med. 1997; 16: 901–910.

    CAS  Google Scholar 

  21. Kasiske BL, Massy ZA, Guijarro C, Ma JZ. Chronic renal allograft rejection and clinical trial design. Kidney Int. 1995; 52: S116–S119.

    CAS  Google Scholar 

  22. Fleming T Surrogate endpoints in clinical trials. Drug Inf. J. 1996; 30: 545–551.

    Article  Google Scholar 

  23. MacPhee IA, Bradley JA, Briggs JD et al. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation. 1998; 66: 1186–1192.

    Article  PubMed  CAS  Google Scholar 

  24. Senn SJ. Inherent problems with active control equivalence studies. Stat. Med. 1993; 12: 2367–2375.

    CAS  Google Scholar 

  25. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigourous methods. BMJ. 1996; 313: 36–39.

    Article  PubMed  CAS  Google Scholar 

  26. Saad R, Gritsch HA, Shapiro R et al. Clinical significance of renal allograft biopsies with `borderline changes’ as defined in the Banff schema. Transplantation. 1997; 64: 992–995.

    Article  PubMed  CAS  Google Scholar 

  27. Altman D, Bland M. Absence of evidence is not evidence of absence. BMJ. 1995; 311: 485.

    Article  PubMed  CAS  Google Scholar 

  28. Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther. Drug Monit. 1998; 20: 459–463.

    Article  CAS  Google Scholar 

  29. Hilbrands LB, Rischen-Vos J, Hene R, Weimar W, Assmann K, Hoitsma AJ. Randomized trial of misoprostol in patients with chronic renal transplant rejection. Transplant. Int. 1996; 9: S41–S44.

    CAS  Google Scholar 

  30. Cook RJ, Farewell VT. Guidelines for monitoring efficacy and toxicity responses in clinical trials. Biometrics. 1994; 50: 1146–1152.

    Article  PubMed  CAS  Google Scholar 

  31. Gaber AO, First MR, Tesi RJ et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998; 66: 29–37.

    Article  PubMed  CAS  Google Scholar 

  32. Armitage P. Attitudes in clinical trials. Stat. Med. 1998; 17: 2675–2683.

    CAS  Google Scholar 

  33. Goetghebeur E, Van Houwelingen H (eds). Proceedings of symposium on analyzing noncompliance in clinical trials. Stat. Med. 1998; 17: 247–389.

    Article  Google Scholar 

  34. Morris C, Christiansen C. Fitting Weibull duration models with random effects. Lifetime Data Anal. 1995; 1: 347–359.

    Article  PubMed  CAS  Google Scholar 

  35. Cook RJ, Lawless JE. Marginal analysis of recurrent events and a terminating event. Stat. Med. 1997; 16: 911–924.

    CAS  Google Scholar 

  36. Ray JG. Prostaglandin El analogs do not improve renal function among either transplant or nontransplant patients: no further trials required. Transplantation. 1998; 66: 476–483.

    Article  PubMed  CAS  Google Scholar 

  37. Chalmers I. The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effect of healthcare. Ann. NY Acad. Sci. 1993; 703: 156–165.

    Article  PubMed  CAS  Google Scholar 

  38. Petitti D. Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis. Oxford: Oxford University Press; 1994.

    Google Scholar 

  39. Cucherat M. Méta-analyse des Essais Thérapeutiques. Evaluation et Statistiques. Paris: Masson; 1997.

    Google Scholar 

  40. Parmar MKB, Toni V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 1998; 17: 2815–2834.

    CAS  Google Scholar 

  41. Senn S. Pharmaco-economics and portfolio management. In: Statistical Issues in Drug Development. Chichester: John Wiley & Sons; 1997; 353–376.

    Google Scholar 

  42. Torrance G. Current experience with guidelines for economic evaluation in Canada. Drug Inform. J. 1996; 30: 507–511.

    Article  Google Scholar 

Download references

Authors
  1. P. Landais
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Jais
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

P. Cochat J. Traeger C. Merieux M. Derchavane

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Landais, P., Jais, J.P. (1999). Methodological approach of clinical trials for renal transplantation. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4643-2_4

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5960-2

  • Online ISBN: 978-94-011-4643-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation